Department of Health written question – answered at on 2 November 2017.
To ask the Secretary of State for Health, if he will make it his policy to ensure that NHS England and Sarepta Therapeutics conduct pricing negotiations at an early stage in the evaluation of Exondys 51.
The National Institute for Health and Care Excellence (NICE) highly specialised technology (HST) evaluation process for eteplirsen (Exondys 51) allows the company to propose a Patient Access Scheme to the Department, or to discuss commercial arrangements with NHS England, if required. The process provides sufficient time to ensure the evaluation is completed on schedule.
Yes1 person thinks so
No1 person thinks not
Would you like to ask a question like this yourself? Use our Freedom of Information site.